Stocktoria
Whitehawk Therapeutics, Inc. WHWK
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-06-26
Whitehawk Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M | $14.0M | $14.0M | $0 | $20.2M | — | — |
| R&D expense | $91.0M | $51.0M | $48.9M | $32.7M | $19.7M | $15.0M | $12.8M | $17.9M | $12.1M | $11.4M |
| SG&A expense | $29.8M | $36.7M | $44.5M | $40.2M | $18.5M | — | — | — | — | — |
| Operating income | -$114.4M | -$67.5M | -$71.9M | -$62.7M | -$111.2M | -$2.5M | -$24.4M | -$11.2M | -$21.4M | -$16.6M |
| Interest expense | — | — | $231,000 | $230,000 | $665,000 | $815,000 | — | — | — | $9,942 |
| Income tax | $0 | $0 | $0 | $0 | $2,000 | $2,000 | — | — | — | — |
| Net income | -$20.6M | -$63.7M | -$65.8M | -$60.5M | -$110.1M | -$3.5M | -$23.3M | -$10.4M | -$21.4M | -$17.0M |
| EPS (diluted) | $-0.33 | $-2.36 | $-2.44 | $-2.69 | $-12.41 | — | — | — | — | — |
| Operating cash flow | -$97.4M | -$59.5M | -$59.7M | -$49.6M | -$22.4M | -$12.7M | -$23.9M | -$5.8M | -$18.9M | -$15.7M |
| Free cash flow | -$98.0M | -$61.2M | -$63.6M | -$50.1M | -$22.5M | -$12.7M | -$24.1M | -$5.8M | -$18.9M | -$15.8M |
| Cash & equivalents | $37.6M | $28.7M | $62.9M | $39.0M | $149.0M | $4.5M | $38.5M | $62.6M | $20.3M | $1.6M |
| Inventory | $0 | $5.3M | $6.4M | $1.9M | $0 | — | — | — | — | — |
| Total assets | $150.8M | $70.3M | $132.4M | $184.2M | $157.9M | $18.8M | $39.9M | $64.1M | $21.0M | $2.4M |
| Total liabilities | $14.5M | $17.8M | $27.2M | $25.9M | $21.5M | $31.3M | $3.4M | $5.5M | — | — |
| Shareholders' equity | $136.3M | $52.5M | $105.2M | $158.4M | $136.4M | -$12.4M | -$9.1M | $58.7M | $17.4M | -$86.2M |
Growth · year-over-year · Revenue CAGR -13.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -72.5% | +6.7% | +60.1% | +8.7% | +0.0% | — | -100.0% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.